Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Non-Current Debt (2021 - 2025)

Legend Biotech filings provide 5 years of Non-Current Debt readings, the most recent being $319.1 million for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 5.94% to $319.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $319.1 million, a 5.94% increase, with the full-year FY2025 number at $319.1 million, up 5.94% from a year prior.
  • Non-Current Debt hit $319.1 million in Q4 2025 for Legend Biotech, up from $142.9 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $319.1 million in Q4 2025 to a low of $17310.0 in Q2 2021.
  • Median Non-Current Debt over the past 5 years was $275.9 million (2023), compared with a mean of $230.9 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 116.61% in 2022 and later tumbled 51.83% in 2025.
  • Legend Biotech's Non-Current Debt stood at $120.5 million in 2021, then skyrocketed by 116.61% to $260.9 million in 2022, then increased by 7.82% to $281.3 million in 2023, then increased by 7.06% to $301.2 million in 2024, then increased by 5.94% to $319.1 million in 2025.
  • The last three reported values for Non-Current Debt were $319.1 million (Q4 2025), $142.9 million (Q3 2025), and $310.3 million (Q2 2025) per Business Quant data.